Trials
1 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “3 g (2 g FEP + 1 g ZID) IV every 8 hours (q8h), infused over 60 ± 5 minutes for 7 to 14 days”In the company’s words, NCT07885891 on ClinicalTrials.gov
- Tested for
- Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
- Main trialPhase 3
- “This is a Phase 3, randomized, double-blind, multicenter, comparative study evaluating cefepime-zidebactam (FEP-ZID) versus ceftazidime-avibactam (CAZ-AVI) with or without colistin in the treatment of adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). Trial participants will be randomized in a 1:1 ratio to receive either FEP-ZID or CAZ-AVI with or without colistin for 7 to 14 days. Colistin will be added to the CAZ-AVI regimen (or matching saline to the FEP-ZID regimen, to maintain blinding) for participants with a baseline pathogen…”In the company’s words, NCT07885891 on ClinicalTrials.gov
- Other names
- Zidebactam-Cefepime
Other drugs for Hospital Acquired Bacterial Pneumonia (HABP)
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- MenABCWY vaccineGSK · Phase 2
- BV100BioVersys AG · Phase 2
- DTcP-Hib-MCV4CanSino Biologics Inc. · Phase 1
- ACYW135XSinovac Life Sciences Co., Ltd. · Phase 1
- Batch 1 ofCanSino Biologics Inc. · Marketed (Phase 4 trial)
Coming up1
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 31 Dec 2027 | Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | |
| Phase 3Completed | 25 Nov 2024 | Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | |
| Phase 1Completed | 17 Feb 2025 | A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026